Les Laboratoires des Médicaments Stériles
13
1
1
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
69%
9 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.
Role: lead
Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
Role: lead
Tunisian Registry of Trans Catheter Aortic Valve Implantation
Role: lead
Optimized-dose Amoxicillin Versus Standard-dose Amoxicillin for Quadruple Therapy in Helicobacter Pylori Eradication
Role: lead
Epidemiologic Register on Diabetes and COVID-19 in Tunisia
Role: lead
Impact of A Nutritional Supplements' Combination (FERTILIS) on Male Infertility
Role: lead
Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®
Role: lead
The Impact of Telemonitoring in the Management of Hypertension
Role: lead
Enoxaparin in the Prevention of Placental Insufficiency in Pregnant Women
Role: lead
Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin
Role: lead
Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome
Role: lead
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
Role: lead
Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)
Role: lead
All 13 trials loaded